Skip to main content

Table 3 Robustness assessment of the proposed chromatographic methods

From: Chromatographic assay of recently approved co-formulation of Vonoprazan fumarate with low dose Aspirin: AGREE, Complex MoGAPI, and RGB 12-model assessments

Parameters tested

HPTLC method

Parameters tested

HPLC method

VON

ASP

VON

ASP

RSD %

peak areas

Rf ± SD

RSD %

peak areas

Rf ± SD

RSD %

peak areas

Rt ± SD

RSD %

peak areas

Rt ± SD

1) Mobile phase composition

[Ethyl acetate: ethanol: Ammonia

(5:5:0.05, 5.5:4.5:0.05, 4.5:5.5:0.05, 5:5:0.1 (v/v))]

1.04

0.54 ± 3.85 × 10–2

0.85

0.83 ± 2.05 × 10–2

1) Mobile phase ratio

[± 0.5% aqueous phase]

0.99

6.60 ± 4.04 × 10–2

1.20

2.51 ± 1.64 × 10–2

2) Mobile phase volume

[15, 20 and 25 mL]

0.89

0.54 ± 1.00 × 10–2

0.99

0.83 ± 5.48 × 10–3

2) Flow rate

[1 ± 0.05 mL/min]

0.89

6.60 ± 5.22 × 10–2

1.22

2.50 ± 1.34 × 10–2

3) Duration of saturation

[30, 40 and 50 min]

0.94

0.55 ± 8.95 × 10–3

1.20

0.84 ± 1.10 × 10–2

3) Column temp.

[25o C ± 5o C]

1.20

6.59 ± 1.14 × 10–2

1.17

2.50 ± 4.47 × 10–3

4) Time from chromatography to scan

[10, 20, 30 and 60 min]

1.25

0.57 ± 4.47 × 10–2

1.24

0.84 ± 8.94 × 10–3

4) pH of the aqueous phase

[6.8 ± 0.2]

1.55

6.57 ± 2.74 × 10–2

0.89

2.51 ± 1.41 × 10–2

5) λ (± 2 nm)

1.01

0.54 ± 8.37 × 10–3

0.99

0.84 ± 1.79 × 10–2

5) λ (± 2 nm)

1.01

6.60 ± 2.17 × 10–2

1.50

2.50 ± 8.37 × 10–3